Levonordefrin; mepivacaine hydrochloride - Generic Drug Details

What are the generic sources for levonordefrin; mepivacaine hydrochloride and what is the scope of freedom to operate?

Levonordefrin; mepivacaine hydrochloride is the generic ingredient in six branded drugs marketed by Solvay, Eastman Kodak, Septodont, Belmora Llc, Dentsply Pharm, and Deproco, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

Summary for levonordefrin; mepivacaine hydrochloride

US Patents:	0
Tradenames:	6
Applicants:	6
NDAs:	6
Clinical Trials:	4
DailyMed Link:	levonordefrin; mepivacaine hydrochloride at DailyMed

Recent Clinical Trials for levonordefrin; mepivacaine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Suez Canal University	N/A
Cairo University	N/A
University of Sao Paulo	N/A

See all levonordefrin; mepivacaine hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for levonordefrin; mepivacaine hydrochloride

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for levonordefrin; mepivacaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eastman Kodak	CARBOCAINE W/ NEO-COBEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	012125-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Belmora Llc	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	084850-002	Oct 21, 1983		DISCN	No	No
Septodont	ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	084697-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Levonordefrin and Mepivacaine Hydrochloride Market Dynamics and Financial Trajectory

Last updated: September 9, 2026

Levonordefrin combined with mepivacaine hydrochloride is a mature dental local-anesthetic product with limited patent value, low regulatory barriers for established manufacturers, and modest commercial growth potential. Revenue is driven by dental procedure volumes, cartridge utilization, distributor access, and manufacturing reliability rather than brand differentiation. Mepivacaine remains commercially relevant because it provides effective local anesthesia with less dependence on epinephrine than many competing products, while levonordefrin supplies vasoconstriction in selected dental procedures.

What is the commercial product containing levonordefrin and mepivacaine hydrochloride?

The relevant product is a dental injectable containing 2% mepivacaine hydrochloride and levonordefrin at a concentration of 1:20,000. It is supplied in dental cartridges for infiltration and nerve-block anesthesia.

Mepivacaine is the local anesthetic. Levonordefrin, also known as alpha-methylnorepinephrine, is the vasoconstrictor. The vasoconstrictor reduces local blood flow, slows systemic absorption, prolongs anesthetic effect, and limits bleeding. The combination is used primarily in dentistry, not as a broad hospital injectable.

Attribute	Product characteristic
Active anesthetic	Mepivacaine hydrochloride
Vasoconstrictor	Levonordefrin
Common combination	2% mepivacaine HCl with levonordefrin 1:20,000
Dosage form	Dental cartridge injection
Main use	Local and regional dental anesthesia
Primary customers	Dental practices, dental service organizations, distributors
Regulatory category	Approved prescription local anesthetic
Commercial status	Mature, largely generic or legacy-branded market

FDA labeling identifies the product as a dental local anesthetic and provides dosing, contraindications, warnings, and administration instructions for dental use.[1]

How large is the market for mepivacaine hydrochloride and levonordefrin?

The combination occupies a narrow segment of the global dental local-anesthetic market. Public companies generally do not report revenue for this specific SKU, and market databases typically combine it with other dental anesthetics such as lidocaine, articaine, prilocaine, and bupivacaine.

The commercial market has four structural characteristics:

1. Demand is linked to dental procedure volume.
2. Unit prices are constrained by generic competition.
3. Product switching is limited by dentist familiarity, cartridge compatibility, and supply availability.
4. The market is more sensitive to manufacturing interruptions than to promotional activity.

Mepivacaine products compete with:

• Lidocaine hydrochloride with epinephrine.
• Articaine hydrochloride with epinephrine.
• Prilocaine with felypressin in selected non-U.S. markets.
• Plain mepivacaine without a vasoconstrictor.
• Bupivacaine for longer-duration anesthesia.
• Septocaine, a leading articaine product in the U.S. dental market.

Articaine with epinephrine has gained importance in dentistry because of its diffusion profile and broad use in infiltration anesthesia. Lidocaine with epinephrine remains a high-volume benchmark. Mepivacaine with levonordefrin retains a role where clinicians prefer mepivacaine’s anesthetic profile or want an alternative vasoconstrictor formulation.

What is the financial trajectory of the product?

The financial trajectory is mature to low-growth. Revenue expansion is likely to come from dental procedure growth, geographic penetration, and supply recovery rather than price increases.

Financial driver	Directional impact
Dental procedure volumes	Positive
Aging population and restorative dentistry	Positive
Generic competition	Negative for price
Dental distributor consolidation	Negative for supplier leverage
Cartridge manufacturing capacity	Can create short-term upside or downside
Brand promotion	Limited
Patent expiry	Removes pricing protection
Regulatory complexity	Moderate but manageable
Product substitution	Persistent competitive pressure

Product-level revenue is not separately disclosed by the major manufacturers. Public financial statements generally aggregate dental anesthetics within broader pharmaceutical, dental, or medical-device segments. This prevents a reliable standalone revenue estimate for the levonordefrin-mepivacaine combination.

The product’s likely economic profile is characterized by high unit volume, low average selling price, and modest gross-margin variability. Manufacturing economics depend on sterile filling, cartridge assembly, packaging, quality-control testing, and distribution. The active pharmaceutical ingredients are established and inexpensive compared with biologics or complex small-molecule therapies. The cartridge and sterile manufacturing process are more important cost centers than discovery research.

When does levonordefrin-mepivacaine lose exclusivity?

The relevant composition and use concepts are old, and the product does not have a commercially meaningful remaining period of new-molecule exclusivity. Mepivacaine was introduced decades ago, and levonordefrin-containing dental formulations have also been marketed for many years.

No current commercial strategy should rely on patent exclusivity for the legacy combination. The competitive position instead depends on:

• FDA-approved manufacturing status.
• Product availability.
• Dental cartridge capacity.
• Distributor contracts.
• Quality history.
• Pharmacist and dentist familiarity.
• Ability to maintain uninterrupted supply.

The FDA’s Orange Book is the principal source for listed patents and approved drug exclusivity. Legacy generic dental-anesthetic products generally have limited or no active patent leverage compared with recently approved drugs.[2]

What is the Orange Book status of mepivacaine and levonordefrin?

The Orange Book evaluates approved drug products, therapeutic equivalence, patents, and exclusivity. For a mature mepivacaine product, the commercial issue is generally approval and supply status rather than a surviving patent estate.

The combination does not have the profile of a modern branded product supported by:

• New chemical entity exclusivity.
• Pediatric exclusivity.
• Active formulation patents.
• Device patents linked to an exclusive delivery platform.
• A substantial Orange Book patent cluster.

Manufacturers marketing equivalent products compete through abbreviated regulatory pathways or legacy approvals, depending on the specific product and regulatory history. Drug establishment registration, current good manufacturing practices, product quality, and labeling compliance remain important even when patent protection is absent.

How many patents cover the product?

No meaningful active patent estate is associated with the historical mepivacaine hydrochloride and levonordefrin combination as a basic dental anesthetic formulation. Any early composition or formulation patents would have expired long ago based on the age of the active ingredients and the product class.

The absence of a strong patent estate does not eliminate all intellectual-property risk. Potential rights could still arise from:

• Cartridge design.
• Packaging and tamper evidence.
• Manufacturing equipment.
• Sterile filling methods.
• Process-control software.
• Improved formulations.
• Combination products using different vasoconstrictors.
• Device-linked administration systems.

Those rights would not ordinarily block competition with the conventional 2% mepivacaine and 1:20,000 levonordefrin injection.

Are there Paragraph IV challenges or generic-entry risks?

Paragraph IV litigation risk is low for the legacy combination because the product is already exposed to long-standing generic competition and lacks an economically important remaining patent barrier.

The main entry risks are commercial rather than patent-based:

• A new supplier may need validated dental cartridge capacity.
• Dentists may resist switching if cartridge dimensions or handling change.
• Distributors may require established supply reliability.
• Regulatory authorities may scrutinize sterile manufacturing deviations.
• A supplier may face difficulty securing active ingredients, glass cartridges, stoppers, or packaging components.

A new entrant would therefore compete on price, availability, quality record, and distributor access. A successful launch would not require a differentiated patent position, but it would require dependable sterile manufacturing and a credible supply plan.

What formulation patents protect mepivacaine and levonordefrin?

The conventional formulation has limited differentiation. The active ingredients, concentration, and dental cartridge presentation are established. Potentially protectable innovations would need to involve a genuine technical improvement, such as:

• Reduced preservative burden.
• Improved stability.
• Longer shelf life.
• Lower extractables from cartridge components.
• Enhanced compatibility with injection devices.
• Alternative vasoconstrictor delivery.
• Novel depot or controlled-release systems.

A standard 2% mepivacaine and levonordefrin cartridge is unlikely to support meaningful new patent exclusivity without a non-obvious technical feature. Regulatory approval of an improved formulation could create a commercial niche, but the market would remain exposed to substitution from other local anesthetics.

What method-of-use patents apply?

Method-of-use patent protection is not a major commercial factor for this product. Dental local anesthesia uses are established and clinically routine. Broad claims covering infiltration anesthesia, nerve blocks, or routine dental procedures would face substantial validity and prior-art challenges.

A narrower method patent could theoretically cover a specific patient population, dosing sequence, procedure, or delivery technique. Such a patent would have limited value unless it produced a measurable clinical advantage and was adopted widely by dental practitioners.

Which companies compete in the market?

Competition is divided among pharmaceutical manufacturers, dental-specialty companies, and distributors. Relevant competitive categories include:

Competitor category	Examples of products or companies
Mepivacaine products	Carbocaine, Polocaine, generic mepivacaine injections
Articaine products	Septocaine and generic articaine formulations
Lidocaine products	Generic lidocaine with epinephrine
Dental-specialty suppliers	Septodont and other dental anesthetic manufacturers
Broad pharmaceutical suppliers	Companies with sterile injectable manufacturing capacity
Distribution channels	Dental distributors, group purchasing organizations, and direct sales

Brand ownership and manufacturing arrangements can change over time. The commercial identity of a product may differ from the legal manufacturer, contract manufacturer, or distributor listed on the package and FDA labeling.

What manufacturing and geographic barriers affect the market?

The primary barrier is sterile injectable production, not active-ingredient discovery. A manufacturer must maintain:

• Validated aseptic processing.
• Sterile cartridge filling.
• Container-closure integrity.
• Stability data.
• Batch-release testing.
• Reliable packaging-component supply.
• FDA-compliant quality systems.

Geographically, the United States is an important market because of its large dental sector and high use of prefilled anesthetic cartridges. Europe, Latin America, and parts of Asia have different preferences regarding mepivacaine, articaine, lidocaine, and vasoconstrictors. Levonordefrin adoption is less uniform internationally than epinephrine-based dental anesthetic use.

Local regulatory requirements, product registrations, language labeling, reimbursement structures, and distributor networks can limit rapid geographic expansion. A manufacturer with an established dental sales force has an advantage over a low-cost entrant without clinical and distribution relationships.

What litigation or settlement agreements affect the product?

There is no widely recognized, commercially significant patent litigation or settlement structure governing the basic levonordefrin-mepivacaine combination. The product’s legal risk is more likely to involve:

• Product-liability claims.
• Manufacturing deviations.
• Sterility failures.
• Labeling disputes.
• Distribution contracts.
• Supply interruptions.
• Regulatory enforcement.

The absence of major patent litigation means that litigation is unlikely to delay generic market entry or preserve premium pricing.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

Low-price generic launch

A manufacturer enters with a lower price and relies on distributor contracts. This strategy can gain share but may produce weak returns if incumbent suppliers match pricing.

Supply-reliability launch

A manufacturer positions itself as a second source after shortages or allocation events. This strategy can support stronger initial uptake because dental practices value continuity, but the advantage may decline when incumbent supply normalizes.

Premium quality launch

A supplier differentiates through packaging, cartridge performance, quality history, or delivery service. Premium pricing would require a clear operational benefit because the active formulation itself is not novel.

The most attractive near-term opportunity is likely supply replacement or geographic expansion rather than patent-protected innovation.

How strong is the patent estate compared with competing dental anesthetics?

The patent estate is weak compared with newer drug-delivery systems but broadly comparable to other mature dental anesthetic products.

Product class	Patent strength	Main commercial protection
Mepivacaine with levonordefrin	Low	Supply, quality, distribution
Generic lidocaine with epinephrine	Low	Manufacturing and contracts
Generic articaine	Low to moderate	Brand recognition and formulation history
Novel sustained-release anesthetic	Potentially moderate to strong	Formulation and delivery patents
Device-integrated anesthetic system	Potentially strong	Device and method patents

Key Takeaways

• Levonordefrin with mepivacaine hydrochloride is a mature dental local-anesthetic combination.
• The standard product contains 2% mepivacaine HCl and levonordefrin at 1:20,000.
• Patent and regulatory exclusivity are not the main commercial drivers.
• Product-level revenue is generally not disclosed by manufacturers.
• Financial performance depends on dental procedure volume, supply continuity, distributor access, and sterile cartridge capacity.
• Generic-entry risk is high, while Paragraph IV and patent-litigation risk are comparatively low.
• The strongest barriers are manufacturing validation, quality systems, and distribution relationships.
• Articaine with epinephrine and lidocaine with epinephrine remain the principal competitive alternatives.
• New commercial value would most likely come from improved delivery, stability, packaging, or supply reliability rather than the conventional formulation itself.

FAQs

Is levonordefrin the same as epinephrine?

No. Levonordefrin is alpha-methylnorepinephrine, while epinephrine is adrenaline. Both can act as vasoconstrictors, but they have different pharmacologic profiles and are used in different dental formulations.

Is mepivacaine with levonordefrin still FDA approved?

FDA-approved products and legacy products can change status by manufacturer and application. The combination has an established U.S. regulatory history, with current product status determined by the applicable FDA labeling and approval records.[1]

Does mepivacaine with levonordefrin have biosimilar competition?

No. Biosimilars apply to biological products. Mepivacaine and levonordefrin are small-molecule drug ingredients, so competition occurs through generic or equivalent injectable products rather than biosimilars.

Can a manufacturer obtain a new patent on the old combination?

A new patent would require a novel and non-obvious technical feature, such as a materially improved formulation, delivery system, stability profile, or manufacturing process. The basic active-ingredient combination is too old to support new composition-of-matter protection.

What is the main investment risk for this product?

The principal risk is low-margin commoditization combined with sterile-manufacturing and supply-chain exposure. A supplier can gain volume after a shortage, but long-term pricing power is limited without a differentiated delivery system or protected formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Mepivacaine hydrochloride and levonordefrin injection prescribing information. FDA Drugs@FDA and product labeling database.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. U.S. Department of Health and Human Services.

5. DailyMed. (n.d.). Mepivacaine hydrochloride and levonordefrin injection product labeling. National Library of Medicine.